Jane Street’s KalVista Pharmaceuticals KALV Stock Holding History

Jane Street’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$491K	Buy	+24,400	New	+$393K	﹤0.01%	8081
2025 Q3	–	Sell	-129,900	Closed	-$1.47M	–	11311
2025 Q2	$1.47M	Buy	129,900 +79,900	+160%	+$977K	﹤0.01%	4934
2025 Q1	$577K	Buy	+50,000	New	+$510K	﹤0.01%	6597
2024 Q4	–	Sell	-499,200	Closed	-$5.78M	–	10018
2024 Q3	$5.78M	Buy	+499,200	New	+$6.28M	﹤0.01%	2629

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street's KALV Position: Q1 2026 in Review

Jane Street sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 31,608 shares — an estimated $509K sold.

Jane Street first reported a position in KALV in Q2 2021 and held it in 12 quarters. The position peaked at $4.09M in Q1 2024. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Jane Street reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jane Street sold 31,608 KalVista Pharmaceuticals shares in Q1 2026, an estimated $509K.
Jane Street first reported a position in KalVista Pharmaceuticals in Q2 2021 and held it in 12 quarters.
Jane Street's KalVista Pharmaceuticals position peaked at $4.09M in Q1 2024.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.